Paper Details
- Home
- Paper Details
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.
Author: ChesnutC H, GenantH K, HarrisS T, JacksonR D, LicataA A, MillerP D, RossP, WasnichR D, WattsN B
Original Abstract of the Article :
PURPOSE: To determine the effect of long-term intermittent cyclic etidronate treatment on spinal bone density and vertebral fracture rates. PATIENTS AND METHODS: Postmenopausal osteoporotic women (n = 423) were randomized initially into a 2-year, double-blind, multicenter study; it was extended to ...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1016/0002-9343(93)90350-x
データ提供:米国国立医学図書館(NLM)
Etidronate Therapy for Postmenopausal Osteoporosis: Building Bone Strength Over Time
In the field of [Bone Health], we face the challenge of [postmenopausal osteoporosis], a condition characterized by weakened bones. This research explores the effectiveness of [long-term intermittent cyclic etidronate treatment] in improving [spinal bone density] and reducing [vertebral fracture rates] in postmenopausal women. The study used [a randomized, double-blind, multicenter trial] to evaluate the impact of etidronate treatment over a four-year period.
The researchers found that etidronate therapy effectively maintained increased bone density in the spine, even after three years of treatment. It also led to an increase in [proximal femur bone density] in etidronate-treated patients. Notably, the etidronate group experienced a significantly lower rate of vertebral fractures compared to the control group.
Stronger Bones, Fewer Fractures
This research demonstrates the long-term benefits of [intermittent cyclic etidronate therapy] in managing postmenopausal osteoporosis. It provides evidence that this treatment can effectively reduce fracture risk and preserve bone density over time.
Building Stronger Bones
This research underscores the importance of effective bone health management in postmenopausal women. It suggests that [intermittent cyclic etidronate therapy] may offer a viable option for reducing fracture risk and preserving bone health over the long term. This is important because, like a camel’s hump storing valuable reserves, strong bones provide a foundation for a healthy and active life.
Dr. Camel's Conclusion
This research provides strong evidence that intermittent cyclic etidronate therapy effectively strengthens bones and reduces fracture rates in postmenopausal women. It highlights the importance of long-term management strategies for osteoporosis to prevent bone loss and maintain bone health over time.
Date :
- Date Completed 1994-01-19
- Date Revised 2019-06-27
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.